

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/780,804
		Filing Date	2/17/2004
		First Named Inventor	Butlin et al.
		Art Unit	1845
		Examiner Name	V. A. Portner
Sheet 1 of 3		Attorney Docket Number	IMIN.P-033-2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
JEP		US-6,262,518	11-16-1993	Chappel	
		US-6,674,700	10-07-1997	Maurel	
		US-6,830,680	11-03-1998	Meyerhoff et al.	
		US-5,840,857	11-24-1998	Arpaia et al.	
		US-5,914,241	08-22-1999	Valkirs	
		US-5,978,876	11-02-1999	Canfield et al.	
		US-6,087,184	07-11-2000	Magginnelli et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
JEP		EP 0043359 A2	01-06-1982	Pharmacia Diagnostics AB	
		WO 88/08534	11-03-1988	Unilever PLC	

Examiner Signature	<i>[Signature]</i>	Date Considered	2/08
--------------------	--------------------	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/780,904
		Filing Date	2/17/2004
		First Named Inventor	Bullin et al.
		Art Unit	1645
		Examiner Name	V. A. Portner
Sheet 2 of 3	Attorney Docket Number	IMIN,P-039-2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T#
VBA		BARTH ET AL., Interassay differences in growth hormone measurement in acromegaly, Annals of Clinical Biochemistry, 1997, Page(s) 156-159, Volume 34, Number 2	
		BERGER ET AL., Variants of Human Chorionic Gonadotropin from Pregnant Women and Tumor Patients recognized by Monoclonal Antibodies, Journal of Clinical Endocrinology and Metabolism, 1993, Page(s) 347-351, Volume 77, Number 2	
		BIRKEN ET AL., Development and Characterization of Antibodies to a Nicked and Hyperglycosylated Form of hCG from a Choriocarcinoma Patient, Endocrinology, 1999, Page(s) 137-144, Volume 10, Number 2	
		BLETHEN ET AL., Circulating Growth Hormone Isoforms in Girls with Turner's Syndrome, Journal of Clinical Endocrinology and Metabolism, 1994, Page(s) 1439-1443, Volume 78, Number 6	
		BOGUSZEWSKI ET AL., 22-kD Growth hormone exclusion assay: a new approach to measurement of non-22kD growth hormone isoforms in human blood, European Journal of Endocrinology, 1998, Page(s) 573-582, Volume 135, Number 3	
		BURGER ET AL., The endocrinology of the menopause, Journal of steroid biochemistry and molecular biology, 1999, Page(s) 31-35, Volume 69, Number 1-6	
		CANONNE ET AL., Biological and immunochemical characterization of recombinant human thyrotrophin, Glycobiology, 1995, Page(s) 473-481, Volume 5, Number 5	
		HASHIMOTO ET AL., Construction of a specific and sensitive sandwich enzyme immunoassay for 20 kDa human growth hormone, Journal of Immunological Methods, 1998, Page(s) 77-85, Volume 221, Number 1-2	
		JANSSON ET AL., Growth hormone (GH) assays: Influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein, Clinical Chemistry, 1997, Page(s) 950-958, Volume 43, Number 6-1	
		KELLY ET AL., On-line post-capillary affinity detection of immunoglobulin G subclasses and monoclonal antibody variants for capillary electrophoresis, Journal of Chromatography A, 1997, Page(s) 207-214, Volume 790	
✓		MATIKAINEN ET AL., Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to Gonadotropin-Releasing Hormone Antagonist and Agonist Treatments in Postmenopausal Women, Journal of Clinical Endocrinology, 1992, Page(s) 820-825, Volume 75, Number 3	

Examiner Signature		Date Considered	2/05
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
† Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.07 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/780,804
		Filing Date	2/17/2004
		First Named Inventor	Butlin et al.
		Art Unit	1645
		Examiner Name	V. A. Portner
Sheet 3 of 3	Attorney Docket Number	JMIN.P-033-2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
VB		MELLADO ET AL., Characterization of Monoclonal Antibodies Specific for the Human Growth Hormone 22K and 20K Isoforms, Journal of Clinical Endocrinology and Metabolism, 1998, Page(s) 1613-1618, Volume 81, Number 4	
		OVERLIE ET AL., The endocrine transition around menopause - a five years prospective study with profiles of gonadotropins, estrogens, androgens and SHBG among healthy women, ACTA Obstetrica et gynecologica Scandinavica, 1999, Page(s) 842-847, Volume 78, Number 7	
		RAFFERTY ET AL., Difference in carbohydrate composition of FSH preparations detected with lectin-ELISA systems, Journal of Endocrinology, 1995, Page(s) 527-533, Volume 145, Number 3	
		ROGER ET AL., Heterogeneity of plasma gonadotropins. Consequences on immunological properties of LH, Journal of Endocrinology, 1994, Page(s) 349-357, Volume 21, Number 3	
		STRASBURGER, Recognizing minorities: the 22-kD growth hormone exclusion assay (GHEA)--an invited commentary, Comment on European Journal of Endocrinology, 1998, Page(s) 536-537, Volume 135	
		WILSON ET AL., Gonadotrophin glycosylation and function (abstract only), 1990	
		ZERFAOUI ET AL., Glycosylation is the Structural Basis for changes in Polymorphism and Immunoreactivity of Pituitary Glycoprotein..., 1986, Page(s) 749-753, Volume 34, Number 9	

Examiner Signature		Date Considered	2/10/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
†Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.